Locoregional Recurrence Risk in Breast Cancer Patients with Estrogen Receptor Positive Tumors and Residual Nodal Disease following Neoadjuvant Chemotherapy and Mastectomy without Radiation Therapy

Table 3

ypN/receptor groups associated with a >10% five-year LRR risk.

	5-year risk of LRR
ypN+
Triple negative	37%
Her2+	33%
ER+, +LVI	13%
ER+, grade 3	11%
ypN0
Her2+	22%
Triple negative, grade 3	13%

LRR, locoregional recurrence; LVI, lymphovascular space invasion.
denotes LRR risk without specification of other adverse pathological features.